The study objectives are to assess: (1) the safety of the treatment; (2) the effects of treatment on the mean change in atrophic lesion area quantified from fundus autofluorescence images; (3) the effects of treatment on the mean change in low luminance best corrected visual acuity (BCVA); (4) the effects of treatment on the mean change in standard BCVA; (5) the effects of treatment on the mean change in retinal sensitivity quatified using scotopic/mesopic microperimetry; (6) to characterize the systemic pharmacokinetic profile of Brimo DDS.